**The July 23, 2026, FDA Pharmacy Compounding Advisory Committee (PCAC) vote is the dominant recent driver.** The panel recommended 8-6 (one abstention) adding BPC-157 (free base and acetate) to the 503A Bulk Drug Substances List for ulcerative colitis compounding, overriding staff concerns over limited human data, small trials, absent safety information for proposed routes, and immunogenicity risks. This followed April 2026 removal from Category 2 after withdrawn nominations, leaving the substance in regulatory limbo without automatic compounding eligibility. Formal notice-and-comment rulemaking after any FDA acceptance typically spans 12–24 months, with no further agency action reported as of early September 2026. Policy emphasis on expanded access and ongoing trials (such as a Phase 2 hamstring study) shape trader views of timelines, though the non-binding nature of the PCAC recommendation and evidentiary gaps keep outcomes uncertain.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於最新
2026-12-31
2026年12月31日
57%
$4,143 交易量
2026年12月31日
$2,141 交易量
57%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.**The July 23, 2026, FDA Pharmacy Compounding Advisory Committee (PCAC) vote is the dominant recent driver.** The panel recommended 8-6 (one abstention) adding BPC-157 (free base and acetate) to the 503A Bulk Drug Substances List for ulcerative colitis compounding, overriding staff concerns over limited human data, small trials, absent safety information for proposed routes, and immunogenicity risks. This followed April 2026 removal from Category 2 after withdrawn nominations, leaving the substance in regulatory limbo without automatic compounding eligibility.
Formal notice-and-comment rulemaking after any FDA acceptance typically spans 12–24 months, with no further agency action reported as of early September 2026. Policy emphasis on expanded access and ongoing trials (such as a Phase 2 hamstring study) shape trader views of timelines, though the non-binding nature of the PCAC recommendation and evidentiary gaps keep outcomes uncertain.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
市場開放時間： Jun 22, 2026, 10:10 PM ET
交易量
$4,143結束日期
2027-01-01市場開放時間
Jun 22, 2026, 10:10 PM ETThis market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.**The July 23, 2026, FDA Pharmacy Compounding Advisory Committee (PCAC) vote is the dominant recent driver.** The panel recommended 8-6 (one abstention) adding BPC-157 (free base and acetate) to the 503A Bulk Drug Substances List for ulcerative colitis compounding, overriding staff concerns over limited human data, small trials, absent safety information for proposed routes, and immunogenicity risks. This followed April 2026 removal from Category 2 after withdrawn nominations, leaving the substance in regulatory limbo without automatic compounding eligibility.
Formal notice-and-comment rulemaking after any FDA acceptance typically spans 12–24 months, with no further agency action reported as of early September 2026. Policy emphasis on expanded access and ongoing trials (such as a Phase 2 hamstring study) shape trader views of timelines, though the non-binding nature of the PCAC recommendation and evidentiary gaps keep outcomes uncertain.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
交易量
$4,143結束日期
2027-01-01市場開放時間
Jun 22, 2026, 10:10 PM ET**The July 23, 2026, FDA Pharmacy Compounding Advisory Committee (PCAC) vote is the dominant recent driver.** The panel recommended 8-6 (one abstention) adding BPC-157 (free base and acetate) to the 503A Bulk Drug Substances List for ulcerative colitis compounding, overriding staff concerns over limited human data, small trials, absent safety information for proposed routes, and immunogenicity risks. This followed April 2026 removal from Category 2 after withdrawn nominations, leaving the substance in regulatory limbo without automatic compounding eligibility. Formal notice-and-comment rulemaking after any FDA acceptance typically spans 12–24 months, with no further agency action reported as of early September 2026. Policy emphasis on expanded access and ongoing trials (such as a Phase 2 hamstring study) shape trader views of timelines, though the non-binding nature of the PCAC recommendation and evidentiary gaps keep outcomes uncertain.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions